seneste årsrapport - Sundhed.dk

Urup T, Madsen G, Hallager S, Schmitz A, Fogd K, Bøgsted M, Nyegaard M, Sørensen KD, Johnsen HE. Cancer
stem cells in the haematopoietic system. Ugeskr Laeger. 2010; 172: 2597-600.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau
H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. Treatment of
relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011; 37: 266-83. (Epub
2010 Sep 21). Review
Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel UB, Werge T,
Rasmussen HB. No influence of genetic polymorphisms CYP2C19 and CYP2D6 on the efficacy of
cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer. 2010; 10: 404
Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, Vogel U, Gimsing P. Improved
survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a
population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol. 2010; 85: 209-216.
Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø, BA, Vogel U. The
importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose
treatment and stem cells support: A linkage disequilibrium mapping in RAI and CD3EAP. Ann. Hematol. (Epub
2010 Nov 3)
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K,
Gulbrandsen N, Haukas E, Hjertner O, Hjorth M, Karlsson T, Knudsen L, Nielsen JL, Linder O, Mellqvist UH,
Nesthus I, Rolke J, Strandberg M, Sorbo JH, Wisloff F, Juliusson G, Turesson I. Melphalan and prednisone plus
thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010; 116: 1405-1412.
2011
Abildgaard, N. Subkutan Velcade behandling ved myelomatose. BestPractice Hæmatologi, 2011; 1: 16-18.
Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial
growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J
Cancer, 2011 [Epub ahead of print]
Boegsted M, Holst JM, Fogd K, Falgreen S, Sørensen S, Schmitz A, Bukh A, Johnsen HE, Nyegaard M, Dybkaer K.
Generation of a predictive melphalanresistance index by drug screen of B-cell cancer cell lines. PLoS One, 2011;
29:e19322.
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M,
Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G,
Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International
Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple
myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011; 117: 6063-73.
Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P,
Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld
P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group;
Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma
Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685
individual patient data from 6 randomized clinical trials. Blood, 2011; 118: 1239-47.
Kristensen, IB. Knoglesygdommen ved myelomatose. Myelomatosebladet, 2011, 3: 12-16.
Dansk Myelomatose Studie Gruppe side 63 Årsrapport 2011